ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab
Phase 3
Completed
- Conditions
- Systemic Juvenile Idiopathic Arthritis (SJIA)
- Interventions
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2019-07-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 182
- Registration Number
- NCT02296424
- Locations
- 🇹🇷
Novartis Investigative Site, Izmir, Turkey
Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2019-07-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT02294786
- Locations
- 🇬🇧
Novartis Investigative Site, Romford, United Kingdom
16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis
Phase 3
Completed
- Conditions
- Arthritis, Psoriatic
- Interventions
- Biological: SecukinumabOther: Placebo
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2019-07-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 341
- Registration Number
- NCT02294227
- Locations
- 🇬🇧
Novartis Investigative Site, Leytonstone, London, United Kingdom
Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 161
- Registration Number
- NCT02292446
- Locations
- 🇹🇭
Novartis Investigative Site, Chiang Mai, Thailand
Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 27
- Registration Number
- NCT02292550
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma
Phase 2
Completed
- Conditions
- Relapse/Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2014-11-14
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT02290431
- Locations
- 🇯🇵
Novartis Investigative Site, Tokushima, Japan
Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome
Phase 2
Completed
- Conditions
- Primary Sjögren's Syndrome
- Interventions
- Drug: CFZ533 active - Cohort 2Drug: CFZ533 placebo - Cohort 2Drug: CFZ533 active - Cohort 1Drug: CFZ533 placebo- Cohort 1Drug: CFZ533 active -Cohort 3Drug: CFZ533 active - Cohort 3
- First Posted Date
- 2014-11-14
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 69
- Registration Number
- NCT02291029
- Locations
- 🇬🇧
Novartis Investigative Site, Newcastle upon Tyne, United Kingdom
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
Phase 3
Completed
- Conditions
- Advanced Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2014-10-29
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 672
- Registration Number
- NCT02278120
- Locations
- 🇺🇸
Penn State University Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸Danbury Hospital SC, Danbury, Connecticut, United States
🇺🇸University Of California Los Angeles Dept of Onc, Los Angeles, California, United States
A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 66
- Registration Number
- NCT02276027
- Locations
- 🇨🇳
Novartis Investigative Site, Guangzhou, Guangdong, China
A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase
- First Posted Date
- 2014-10-23
- Last Posted Date
- 2019-08-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 225
- Registration Number
- NCT02272777
- Locations
- 🇨🇳
Novartis Investigative Site, Shanghai, China